Cerity Partners’s Perspective Therapeutics CATX Stock Holding History

Cerity Partners’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,000	Closed	-$47.6K	–	2253
2024 Q1	$47.6K	Hold	4,000	–	–	﹤0.01%	2249
2023 Q4	$16.1K	Buy	+4,000	New	+$11.3K	﹤0.01%	1838
2023 Q3	–	Sell	-4,000	Closed	-$26.7K	–	1431
2023 Q2	$26.7K	Hold	4,000	–	–	﹤0.01%	1596
2023 Q1	$25.5K	Hold	4,000	–	–	﹤0.01%	1819
2022 Q4	$9.88K	Hold	4,000	–	–	﹤0.01%	1470
2022 Q3	$9K	Hold	4,000	–	–	﹤0.01%	1172
2022 Q2	$12K	Hold	4,000	–	–	﹤0.01%	1171
2022 Q1	$15K	Hold	4,000	–	–	﹤0.01%	930
2021 Q4	$16K	Hold	4,000	–	–	﹤0.01%	1013
2021 Q3	$25K	Hold	4,000	–	–	﹤0.01%	678
2021 Q2	$32K	Hold	4,000	–	–	﹤0.01%	705
2021 Q1	$44K	Hold	4,000	–	–	﹤0.01%	689
2020 Q4	$18K	Hold	4,000	–	–	﹤0.01%	637
2020 Q3	$23K	Hold	4,000	–	–	﹤0.01%	499
2020 Q2	$22K	Buy	+4,000	New	+$25.7K	﹤0.01%	449

Other funds holding CATX

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cerity Partners's CATX Position: Q2 2024 in Review

Cerity Partners sold out of Perspective Therapeutics (CATX) in Q2 2024, closing a stake of 4,000 shares — an estimated $47.6K sold.

Cerity Partners first reported a position in CATX in Q2 2020 and held it in 15 quarters. The position peaked at $47.6K in Q1 2024. 105 funds tracked by Wall St. Rank hold CATX as of Q2 2024.

Cerity Partners reported no remaining Perspective Therapeutics position as of Q2 2024 after selling out during the quarter.
Cerity Partners sold 4,000 Perspective Therapeutics shares in Q2 2024, an estimated $47.6K.
Cerity Partners first reported a position in Perspective Therapeutics in Q2 2020 and held it in 15 quarters.
Cerity Partners's Perspective Therapeutics position peaked at $47.6K in Q1 2024.
105 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2024.

Based on Cerity Partners's 13F filing for Q2 2024, filed 13 Aug 2024.